[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-lesions-located-at-the-body-or-the-tail\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-lesions-located-at-the-body-or-the-tail":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100634619","artidis-nanomechanical-signature-profiling-of-pancreatic-cancer-specimens-100634619",false,"NCT07542041","Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens","Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens (ANoPs)","ANoPs","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to understand and willingness to sign a written informed consent form\n* Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy.\n\nThe main questions this study aims to answer are:\n\n* Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer?\n* How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment?\n\nThis is a prospective, single-arm study. Researchers will compare results from the NEO-Match® test with standard clinical outcomes, imaging findings, and pathology results to evaluate its predictive and diagnostic performance.\n\nParticipants will:\n\n* Undergo a standard-of-care pancreatic biopsy or surgical procedure\n* Provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device\n* Continue to receive standard treatment and care, which is not influenced by the study\n* Have clinical data, imaging results, and treatment outcomes collected\n* Be followed every 3 months for up to 2 years\n\nThe study does not involve experimental treatment or changes to standard medical care. The information collected may help improve future diagnosis, prognosis, and treatment selection for patients with pancreatic cancer.",[27,28,29,30],"Pancreatic Cancer","Pancreatic Neoplasms","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Lesions Located at the Body or the Tail",[32,33,34,35,36,27],"Atomic Force Microscopy","Neoadjuvant Therapy","Nanomechanical Profiling","NEO-Match","Pancreatic Ductal Adenocarcinoma","RECRUITING","2026-04-14",{"date":40,"type":41},"2026-04-21","ACTUAL",{"date":43,"type":21},"2026-04",{"date":45,"type":21},"2030-05",{"name":47,"class":48},"ARTIDIS AG","INDUSTRY",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100625578","comparison-between-triphasic-ct-abdomen-and-eus-fnb-in-characterization-of-pancreatic-lesion-100625578","NCT07424456","Comparison Between Triphasic CT Abdomen and EUS-FNB in Characterization of Pancreatic Lesion","Inclusion Criteria:\n\n* \\*Adult patients (age\\>18 years) presenting with focal pancreatic lesions detected on initial imaging.\n\n  * Patients referred for further evaluation by triphasic CT and\u002For EUS-guided biopsy.\n  * Patients able to provide informed consent\n\nExclusion Criteria:\n\n* Previous pancreatic surgery.\n\n  * Known metastatic disease at presentation.\n  * Contraindications to contrast-enhanced CT (e.g. severe renal impairment, contrast allergy)\n  * Contraindications to EUS or biopsy (e.g., coagulopathy uncorrected, severe cardiopulmonary instability).\n  * Pregnancy.",{"count":57,"type":21},50,"OBSERVATIONAL","evaluate the relationship between triphasic CT and EUS findings and the characterization of pancreatic lesions.",[61,62,30],"EUS Guided Biopsy","CT Scan",[64,65],"Triphasic Ct abdomen vs EUS-FNB","EUS-FNB","NOT_YET_RECRUITING","2026-02-13",{"date":69,"type":41},"2026-02-20",{"date":71,"type":21},"2026-02-01",{"date":73,"type":21},"2027-04-01",{"name":75,"class":76},"Assiut University","OTHER"]